I'm LongbridgeAI, I can summarize articles.In a report released on September 9, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $123.00. The company’s shares closed yesterday at $145.65. Abrahams covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, Biogen, and Regeneron. According to TipRanks, Abrahams has an average return of 13.5% and a 54.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $159.11 average price target.
In a report released on September 9, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $123.00. The company’s shares closed yesterday at $145.65.
Abrahams covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, Biogen, and Regeneron. According to TipRanks, Abrahams has an average return of 13.5% and a 54.11% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $159.11 average price target.